These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28130640)

  • 21. FUS pathology defines the majority of tau- and TDP-43-negative frontotemporal lobar degeneration.
    Urwin H; Josephs KA; Rohrer JD; Mackenzie IR; Neumann M; Authier A; Seelaar H; Van Swieten JC; Brown JM; Johannsen P; Nielsen JE; Holm IE; ; Dickson DW; Rademakers R; Graff-Radford NR; Parisi JE; Petersen RC; Hatanpaa KJ; White CL; Weiner MF; Geser F; Van Deerlin VM; Trojanowski JQ; Miller BL; Seeley WW; van der Zee J; Kumar-Singh S; Engelborghs S; De Deyn PP; Van Broeckhoven C; Bigio EH; Deng HX; Halliday GM; Kril JJ; Munoz DG; Mann DM; Pickering-Brown SM; Doodeman V; Adamson G; Ghazi-Noori S; Fisher EM; Holton JL; Revesz T; Rossor MN; Collinge J; Mead S; Isaacs AM
    Acta Neuropathol; 2010 Jul; 120(1):33-41. PubMed ID: 20490813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neuron loss and degeneration in the progression of TDP-43 in frontotemporal lobar degeneration.
    Yousef A; Robinson JL; Irwin DJ; Byrne MD; Kwong LK; Lee EB; Xu Y; Xie SX; Rennert L; Suh E; Van Deerlin VM; Grossman M; Lee VM; Trojanowski JQ
    Acta Neuropathol Commun; 2017 Sep; 5(1):68. PubMed ID: 28877758
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS.
    Al-Sarraj S; King A; Troakes C; Smith B; Maekawa S; Bodi I; Rogelj B; Al-Chalabi A; Hortobágyi T; Shaw CE
    Acta Neuropathol; 2011 Dec; 122(6):691-702. PubMed ID: 22101323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43.
    Tan RH; Shepherd CE; Kril JJ; McCann H; McGeachie A; McGinley C; Affleck A; Halliday GM
    Acta Neuropathol Commun; 2013 Jul; 1(1):33. PubMed ID: 24252630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spatial patterns of TDP-43 neuronal cytoplasmic inclusions (NCI) in fifteen cases of frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP).
    Armstrong RA; Cairns NJ
    Neurol Sci; 2011 Aug; 32(4):653-9. PubMed ID: 21647631
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of TMEM106B, the frontotemporal lobar degeneration-associated protein, in normal and diseased human brain.
    Busch JI; Martinez-Lage M; Ashbridge E; Grossman M; Van Deerlin VM; Hu F; Lee VM; Trojanowski JQ; Chen-Plotkin AS
    Acta Neuropathol Commun; 2013 Jul; 1():36. PubMed ID: 24252750
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reappraisal of TDP-43 pathology in FTLD-U subtypes.
    Mackenzie IR; Neumann M
    Acta Neuropathol; 2017 Jul; 134(1):79-96. PubMed ID: 28466142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TDP-43-positive white matter pathology in frontotemporal lobar degeneration with ubiquitin-positive inclusions.
    Neumann M; Kwong LK; Truax AC; Vanmassenhove B; Kretzschmar HA; Van Deerlin VM; Clark CM; Grossman M; Miller BL; Trojanowski JQ; Lee VM
    J Neuropathol Exp Neurol; 2007 Mar; 66(3):177-83. PubMed ID: 17356379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of TDP-43 seeding activity in the olfactory mucosa from patients with frontotemporal dementia.
    Fontana E; Bongianni M; Benussi A; Bronzato E; Scialo C; Sacchetto L; Cagnin A; Castriciano S; Buratti E; Gardoni F; Italia M; Schreiber A; Ferracin C; Fiorini M; Newell KL; Cracco L; Garringer HJ; Cecchini MP; Polymenidou M; Padovani A; Monaco S; Legname G; Ghetti B; Borroni B; Zanusso G
    Alzheimers Dement; 2024 Feb; 20(2):1156-1165. PubMed ID: 37908186
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Senile onset frontotemporal lobar degeneration with TAR-DNA binding protein 43 proteinopathy primarily presenting with wasteful habits.
    Iwasaki Y; Mori K; Ito M; Tatsumi S; Mimuro M; Yoshida M
    Psychogeriatrics; 2013 Dec; 13(4):260-4. PubMed ID: 24289467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frontotemporal Lobar Degeneration TDP-43-Immunoreactive Pathological Subtypes: Clinical and Mechanistic Significance.
    Neumann M; Lee EB; Mackenzie IR
    Adv Exp Med Biol; 2021; 1281():201-217. PubMed ID: 33433877
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neurocognitive speed associates with frontotemporal lobar degeneration TDP-43 subtypes.
    Dean PM; Smith GE; Parisi JE; Dickson DW; Petersen RC; Josephs KA
    J Clin Neurosci; 2013 Dec; 20(12):1737-41. PubMed ID: 24012243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes.
    Neumann M; Frick P; Paron F; Kosten J; Buratti E; Mackenzie IR
    Acta Neuropathol; 2020 Nov; 140(5):645-658. PubMed ID: 32778941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Amyotrophic lateral sclerosis features predict TDP-43 pathology in frontotemporal lobar degeneration.
    Long Z; Irish M; Hodges JR; Halliday G; Piguet O; Burrell JR
    Neurobiol Aging; 2021 Nov; 107():11-20. PubMed ID: 34371283
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cortical degeneration in frontotemporal lobar degeneration with TDP-43 proteinopathy caused by progranulin gene mutation.
    Armstrong RA
    Int J Neurosci; 2014 Dec; 124(12):894-903. PubMed ID: 24494724
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical features of the behavioural variant of frontotemporal dementia that are useful for predicting underlying pathological subtypes of frontotemporal lobar degeneration.
    Kobayashi Z; Arai T; Kawakami I; Yokota O; Hosokawa M; Oshima K; Niizato K; Shiraishi A; Akiyama H; Mizusawa H
    Psychogeriatrics; 2018 Jul; 18(4):307-312. PubMed ID: 30133939
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drosha inclusions are new components of dipeptide-repeat protein aggregates in FTLD-TDP and ALS C9orf72 expansion cases.
    Porta S; Kwong LK; Trojanowski JQ; Lee VM
    J Neuropathol Exp Neurol; 2015 Apr; 74(4):380-7. PubMed ID: 25756586
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A morphometric study of the spatial patterns of TDP-43 immunoreactive neuronal inclusions in frontotemporal lobar degeneration (FTLD) with progranulin (GRN) mutation.
    Armstrong RA; Cairns NJ
    Histol Histopathol; 2011 Feb; 26(2):185-90. PubMed ID: 21154232
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study.
    Kuiperij HB; Versleijen AA; Beenes M; Verwey NA; Benussi L; Paterlini A; Binetti G; Teunissen CE; Raaphorst J; Schelhaas HJ; Küsters B; Pijnenburg YA; Ghidoni R; Verbeek MM
    J Alzheimers Dis; 2017; 55(2):585-595. PubMed ID: 27662293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological characteristics of FTLD-TDP showing corticospinal tract degeneration but lacking lower motor neuron loss.
    Kobayashi Z; Tsuchiya K; Arai T; Yokota O; Yoshida M; Shimomura Y; Kondo H; Haga C; Asaoka T; Onaya M; Ishizu H; Akiyama H; Mizusawa H
    J Neurol Sci; 2010 Nov; 298(1-2):70-7. PubMed ID: 20810131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.